35.172.230.21
dgid:
enl:
npi:0
-Advertisement-
-Advertisement-
Dermatology

Post-market study confirms NEAUVIA Intense effectiveness for nasolabial fold correction

Posted on

NEAUVIA Intense, a PEG cross-linked polymeric hydrogel, has been validated as a safe and effective injectable filler for correcting moderate-to-severe nasolabial folds (NLF), providing significant and lasting improvements in tissue depression and aesthetic outcomes without any observed adverse effects, according to results of a post-market study.

A recent prospective, single-center study focused on aesthetic outcomes, patient satisfaction, and potential adverse events associated with the injectable filler. Out of 70 initially enrolled patients, 60 met the study parameters. Each participant received a single session treatment with NEAUVIA Intense on both sides of the NLF.

The study reported a statistically significant improvement in tissue depression immediately after injection (P < 0.001), with effects persisting for up to 6 months. Modified Fitzpatrick Wrinkle Scale assessments showed a high percentage of responders: 96.6% immediately post-treatment, 76.6% after 1 month, 48.3% after 3 months, and 28.3% at 6 months (P < 0.001). Global Aesthetic Improvement Scale assessments indicated maximum improvement at 30 and 90 days post-treatment. Both patient and physician satisfaction remained stable over time, with minor fluctuations at 4 and 24 weeks (P < 0.001, Anova; P < 0.05, Wilcoxon). No adverse effects related to NEAUVIA Intense were observed throughout the follow-up period.

The authors concluded that “the findings contribute to the understanding of this specific hydrogel filler and highlight the broader context of injectable fillers in comprehensive facial aesthetic strategies.”

Reference
Zerbinati N, Płatkowska A, Guida S, et al. Efficacy and Safety of Neauvia Intense in Correcting Moderate-to-Severe Nasolabial Folds: A Post-Market, Prospective, Open-Label, Single-Centre Study. Clin Cosmet Investig Dermatol. 2024;17:1351-1363. doi: 10.2147/CCID.S460973. PMID: 38881701; PMCID: PMC11178092.

 

 

-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-